Cancer care and screenings must remain a priority during COVID-19

Nation’s top cancer hospital remains committed to providing patients high-level, safe care
University of Texas M. D. Anderson Cancer Center

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel coronavirus (COVID-19) pandemic. In light of emerging research showing many people are delaying cancer screenings and other health care needs, MD Anderson is reminding both cancer patients and the healthy public that it is safe to keep scheduled appointments for active treatment or routine care.

“We know cancer doesn’t stop – even during a global pandemic,” said Peter WT Pisters, M.D., president of MD Anderson. “Our patient population represents the largest and densest immunocompromised population in the world. We are committed to providing exceptional cancer care, and that includes going above and beyond to create the safest possible environment for our patients and our workforce.”

Cancer patients are uniquely vulnerable to COVID-19 because their immune systems are compromised due to disease and/or treatment. From the beginning, MD Anderson’s COVID-19 precautions have been guided by three principles:

  1. Protect our patients.
  2. Ensure the health of our workforce.
  3. Reduce the impact of COVID-19 on our community.

“It’s safe to receive cancer care and treatment at MD Anderson,” said Rosanna Morris, chief operating officer at MD Anderson. “When patients come to MD Anderson, they are greeted by teams screening for COVID-19 symptoms and providing masks. We want anyone in our institution to feel absolutely confident they’re in a safe place, even when there’s a pandemic going on outside.”       

COVID-19 safety precautions

MD Anderson began monitoring and educating patients and employees about the pandemic in January, and began implementing measures to protect against the spread of COVID-19 in February. Since the start of the pandemic, more than 1.2 million COVID-19 screenings have been performed across all MD Anderson locations.

Key precautions include:

  • Verbally screening for COVID-19 symptoms
  • Quickly detecting elevated skin temperatures using no-contact thermal imaging technology as people walk into the building
  • Wearing medical-grade masks provided by MD Anderson
  • Practicing social distancing guidelines

COVID-19 nasal swab testing is performed onsite for symptomatic patients and employees. MD Anderson also provides asymptomatic COVID-19 testing to patients and employees, as evidence has shown it’s possible to transmit the virus before showing symptoms. To ensure safety, all patients are required to have a COVID-19 test before their new patient appointment, surgery, and certain procedures and treatments. Employees can request asymptomatic COVID-19 testing for themselves for any reason.

Clinical trials continue to be a priority at MD Anderson. Toward the beginning of the pandemic and out of an abundance of caution, many clinical trials were modified to use remote monitoring and virtual care. Now, more than 900 clinical trials have reopened for enrollment.

To further protect our patients and employees, and to reduce the spread of infection, MD Anderson has limited visitors on campus, expanded virtual patient care options and transitioned employees in non-patient care roles to remote work. Clinics and operating rooms have expanded hours to space out appointments and to lower the number of people on campus at one time. Additional COVID-19 precautions are shared on our dedicated coronavirus website.

Importance of cancer screenings and preventive care

Recent research has shown that new cancer diagnoses have declined since the beginning of the pandemic, possibly due to delayed cancer screenings and other routine health care appointments. A model from the National Cancer Institute estimated that delayed diagnoses due to the COVID-19 pandemic could result in 10,000 excess deaths from breast and colorectal cancer over the next 10 years.

Cancer screening exams help find cancer early, when the chances for successfully treating the disease are greatest. MD Anderson offers screening exams for several different types of cancer, including mammograms for breast cancer, colonoscopy for colorectal cancer, and skin cancer exams at multiple Houston-area locations.

“Cancer screenings may not be top of mind at the moment, but if you’ve been putting off a recommended screening exam, now is the time to make it a priority,” said Therese Bevers, M.D., medical director of the Cancer Prevention Center. “Delaying recommended cancer screenings may result in missed early-stage cancers that aren’t caught until they’re already more advanced, and potentially more difficult to treat.”

Whether or not you’ve ever faced a cancer diagnosis, it’s important to pay attention to changes in your body and symptoms that may indicate something is wrong. Common symptoms that could indicate cancer or another problem and should be brought to your doctor’s attention include: a mass or lump, unexplained weight loss, pain, change in bowel or bladder habits, a sore that doesn’t heal, a persistent cough, or unusual bleeding or discharge.

“We don’t want people to be diagnosed with cancers at later stages because they avoided visiting the doctor due to COVID-19,” Bevers said. “We are providing a safe environment so you can feel protected from COVID-19 while taking care of your cancer risk, too.” 

            

- 30 -

 

About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).




Filters close

Showing results

110 of 3321
Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.

Released: 17-Sep-2020 5:50 PM EDT
AERA and OECD to Co-Host Webinar on Education Research Worldwide in a Covid and Post-Covid World
American Educational Research Association (AERA)

The American Educational Research Association (AERA) and the Organisation for Economic Co-operation and Development (OECD) will co-host a webinar on “Education Research Worldwide in a Covid and Post-Covid World” at 9:30-11:00 am EDT Wednesday, September 23.

Newswise: 243232_web.jpg
Released: 17-Sep-2020 4:20 PM EDT
Study shows first proof that a safer UV light effectively kills virus causing COVID-19
Hiroshima University

A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 -- the first research in the world to prove its efficacy against the virus that causes COVID-19.

Newswise:Video Embedded american-academy-of-dermatology-honors-detroit-physician-iltefat-h-hamzavi-with-national-patient-care-hero-award
VIDEO
Released: 17-Sep-2020 4:00 PM EDT
American Academy of Dermatology honors Detroit physician Iltefat H. Hamzavi with national “Patient Care Hero” award
American Academy of Dermatology

The American Academy of Dermatology has named board-certified dermatologist Iltefat H. Hamzavi, MD, FAAD, a Patient Care Hero for his innovative use of light therapy to sanitize masks needed by frontline health care workers.

access_time Embargo lifts in 2 days
Embargo will expire: 22-Sep-2020 11:00 AM EDT Released to reporters: 17-Sep-2020 3:20 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 22-Sep-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 17-Sep-2020 3:05 PM EDT
New York State Department of Health Grants Emergency Use Authorization to Mount Sinai for Quantitative COVID-19 Antibody Test
Mount Sinai Health System

The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood


Showing results

110 of 3321

close
1.09947